Clinical Scientist, Sepsis

• Medical degree (MD) with relevant specialisation.
• Documented record of accomplishment in drug development programmes, demonstrating an in-depth understanding of translating early-stage programmes into the clinic and progressing them across the clinical development chain.
• Working knowledge of ICH-GCP, applicable clinical trial regulations and the sponsor obligations attached to protocol design, medical monitoring and study reporting.

• Clinical or research experience in intensive care medicine, anaesthesiology, infectious diseases, internal medicine or emergency medicine.
• Experience in acute or critical care interventional trials, including mortality-based endpoints, adaptive or platform designs and emergency consent frameworks.
• Understanding of the immunology and pathophysiology of sepsis, including immune dysregulation, hyperinflammatory and immunosuppressed phenotypes, and biomarker-guided patient selection.
• Expertise in pharmacokinetics and pharmacodynamics, including altered PK in critically ill patients (for example capillary leak, altered volume of distribution, renal replacement therapy).
• Ability to bring a medical and scientific perspective and drug development judgement to business development, corporate strategy and leadership decision-making.

Skills, knowledge and languages

• Strong written and verbal communication skills, with demonstrated ability to represent the company credibly to internal and external audiences, including international conferences, scientific symposia and collaborations.
• Strong organisational and project management skills, with the ability to prioritise across concurrent studies and to act as a self-motivated driver of best practice.
• Demonstrated ability to lead and influence cross-functional teams without direct line authority.
• Sound quantitative literacy: able to interrogate statistical analysis plans, interim outputs and data trends in dialogue with Biostatistics.
• Professional proficiency in written and spoken English.

• Ability to demonstrate behaviours in line with Sobi's core values: Care, Ambition, Urgency, Ownership and Partnership.
• Additional language skills relevant to key clinical trial regions.

Personal attributes

• Strong team player with high personal and scientific integrity.
• Comfortable operating in a fast-paced environment with shifting priorities and time-critical decisions.
• Intellectual honesty in the interpretation of uncertain or incomplete data, including willingness to state limitations and revise positions in light of evidence.
• Resilience and sound judgement when working with data from a severely ill patient population.
• International travel is expected for investigator meetings, advisory boards, site visits, congresses and Health Authority interactions. Indicative volume to be confirmed by the hiring manager.
• Because sepsis studies enrol in intensive care and emergency settings, occasional out-of-hours availability for urgent medical or safety queries may be required. Any on-call expectation should be defined locally in line with applicable labour law.
• The role is office-based or hybrid, with periodic clinical site presence. Working arrangements follow the applicable local Sobi policy.

Sobi is an international biopharmaceutical company, dedicated to providing access to innovative treatments that transform life for people with rare diseases in the areas of haematology, immunology and specialty care.

With our head office in Stockholm, Sweden, Sobi also has premises in Basel, Switzerland.

You can find more information about Sobi at www.sobi.com.

The Clinical Scientist, Sepsis is accountable for the design, execution and reporting of Sobi-sponsored clinical studies within the sepsis therapeutic area, and acts as a scientific and medical subject-matter expert for the assigned development programme across operational, regulatory and drug safety matters.

The role operates in a therapeutic area characterised by high unmet need, high background mortality, heterogeneous patient populations and no established precedent of approved disease-modifying therapies.

The position therefore carries an explicit expectation of methodological rigour: precise definition of target populations and endpoints, defensible assumptions underpinning trial design, and transparent handling of uncertainty in interpreting emerging data.

The position reports to the TA Head, Sepsis and works within the Medical Development Team and Clinical Study Teams, in close partnership with Clinical Operations, Biostatistics, Regulatory Affairs, Patient Safety, Translational Medicine and external investigators.